Select Your Preferred Language

Please choose your language to continue.

Russia's mRNA vaccine “Enteromix” shows 100% success in preclinical trials | Current Affairs | Vision IAS
News Today Logo

Russia's mRNA vaccine “Enteromix” shows 100% success in preclinical trials

Posted 09 Sep 2025

1 min read

It uses mRNA technology to stimulate immune responses against cancer.

  • Initially targeting colorectal cancer, it is fully personalized, with each dose tailored to a patient’s tumor through mutation profiling.

About mRNA Vaccines

  • mRNA vaccines are a type of vaccine that use a small piece of messenger RNA (mRNA) to instruct our cells to produce a protein specific to a virus.
    • mRNA (messenger Ribonucleic Acid) is a genetic molecule that contains instructions or recipe that directs cells to make a protein using its natural machinery.
  • mRNA delivers genetic material, encapsulated in lipid nanoparticles, into body to prompt protein production that match up with parts of pathogen called antigens.
    • E.g., the mRNA vaccine for COVID-19 directed cells to produce copies of a protein on the outside of the coronavirus known as the spike protein.
  • Immune system sees these foreign antigens as invaders, dispatching defenders called antibodies and T-cells and training immune system for potential future attacks.

Challenges of mRNA vaccines:

  • Storage requirements: Require ultra-cold storage, making distribution difficult.
  • Short-term side effects: E.g. fever, fatigue, and soreness at the injection site.
  • Long-term safety: mRNA vaccines are relatively new, so long-term effects are still being studied.
  • Tags :
  • Cancer
  • Russia
  • mRNA vaccine “Enteromix”
  • mRNA technology
Watch News Today
Subscribe for Premium Features

Quick Start

Use our Quick Start guide to learn about everything this platform can do for you.
Get Started